PPCB Propanc Biopharma Inc

Tracking a total of 13(!!!) reverse splits on Monday - 11 on NASDAQ and 2 on the NYSE American. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am Monday morning. Will have to split this summary into 3 parts. Part 3 of 3: $PPCB 1 for 10. Will reduce outstanding shares from approx 10.33m to approx 1.03m. $SBFM 1 for 20. Will reduce outstanding shares from approx 15.22m to approx 1.52m. $SXTC 1 for 100. Will reduce outstanding Class A shares from approx 68.68m to approx 687k. $TWG 1 for 100. Will reduce outstanding Class A shares from approx 59.58m to approx 596k.

$PPCB Yo, be respectful with the stock, quote the full history! 1.8 quintillion to one in reverse splits, that's 10 with 18 zeroes :D This should be a lesson to all of us when we spark that thing in the head "maybe it won't crash/how low can it go" -- I'm out of it for a big loss and now short it sporadically (for guaranteed greens). CJMB also caught me recently , same institution ex_crement Hextone.

$PPCB thats how they do it, when everyone gets sick and tired of it and takes it off watch list, they cover

$PPCB highlighted preclinical data showing PRP reprograms chemo-resistant pancreatic cancer cells, paving way for a Phase 1b trial.

$PPCB Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer

$PPCB $PPCB 🧬💥 Read this carefully: PRP is NOT trying to replace chemotherapy. PRP appears to make chemotherapy work AGAIN. Let that sink in. Cancer cells that learned how to survive treatment were reportedly reprogrammed and made vulnerable once more. That's potentially a MASSIVE breakthrough mechanism. ✅ Reduced proliferation ✅ Reduced invasion ✅ Reversed aggressive cancer traits ✅ Restored therapeutic vulnerability Wall Street sleeps on microcaps until the data becomes impossible to ignore. PPCB market cap = tiny. Addressable market = enormous. If clinical results confirm the science, this could be one of those stocks people wish they bought before the crowd noticed. Not financial advice. Just connecting the dots. 👀🚀🚀🚀 #PPCB

$PPCB I've got an idea since this Hexstone also drilled to the ground CJMB this week, same, shameless sell no matter time or price ..... .. not wait even to pay the reverse split fee on my broker.. just dump what's left..... .... and start a shorting rampage Monday, rotate like a MM, commissions free, in-out on keyboard. This stock never held high. There is the 6.5M Hexstone on top of the 10M (adjusted Monday to 1.65M). They never held a high even one day, red closing after any spike (if any to be expected). Yea, somehow I know they won't be hurt, they did splits in total of quadrillion to one, that's 10 followed by 15 zeroes. Though it's opportunity, why getting trapped on the low when on short it's guaranteed it won't hold much the pain? ..if you averaged at.. let's say $1 ... now Monday you want to break even at $10 . It has no chance to go there. Orr, as a trader, if it goes just jump on the signal, never hope just observe. Good luck! I mean, good attention! :)

$PPCB Another stock split. My goodness. I lost a mountain of money because i didn't do my due diligence last year. It would have taken 1 minute to see what a scam this company is. That mistake will haunt me forever, and I will never recover what I lost. The 1 owner...yes...1 owner...is trying to fight cancer. This loss almost gave me a heart attack, caused depression, and maybe cancer 1 day. Stay very far away.

$PPCB Dumpster fire :)) Their AI just said : "During FY2026, $PPCB raised $7.5M in gross proceeds. Since June 30, the Company has received an additional $2M through its Series C facility, which the Company expects to support planned R&D activities," From WHO's money? From dilution since they have zero revenue. Dilution = they sell some paper [promises] to you and then take THE SAME paper and sell it to somebody else also. | Claiming that: don't worry, all of you are lucky! :)) And it's not even actually "TRUE", it's fraud. It's like this: FORM 10-K | For the fiscal year ended June 30, 2026 "Repurchase Plan Between July 2026 and August 2026, the Company repurchased 320,031 shares of its common stock under the Repurchase Plan for an aggregate purchase price of approximately $500,000, at an average purchase price of $1.56 per share." next paragraph: "Shares issued for services On July 24, 2026, the Company issued an aggregate of 3,500,000 shares of common stock to (..) directors (..).

$PPCB Propanc Biopharma Announces New Preclinical Data Supporting Potential Of PRP To Treat Chemotherapy Resistance In Pancreatic Cancer; PRP Monotherapy Reduced Cancer Cell Proliferation By ~50–54% And Suppressed Long-term Clonogenic Survival By Up To 59% BENZINGA 7:32 AM ET 10/26/2026

$PPCB Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability

Progress isn't linear. Especially in clinical development. For $PPCB, Nasdaq compliance is one challenge. Securing the capital needed to advance PRP toward its planned Phase 1b first-in-human trial in Q1 2027 is another. Access to capital is essential to support several critical steps: • Advancing GMP manufacturing preparations for PRP. • Completing regulatory and ethics approval processes. • Preparing clinical trial sites for patient enrollment. The reverse split addresses a listing requirement. Capital supports the work needed to reach the clinic. And each completed milestone brings PRP closer to its next objective: evaluation in up to 50 patients with advanced solid tumors. $PPCB

What do the latest findings mean for $PPCB beyond the science? PRP’s potential to remodel chemotherapy-resistant cancer cells could expand its development opportunities in three ways: • Broader applications: Potential use as a standalone or sequential treatment. • Scientific differentiation: Targeting multiple mechanisms associated with treatment resistance. • Strategic value: Potential to complement existing chemotherapy approaches and broaden PRP’s therapeutic positioning. The opportunity goes beyond treating cancer. It’s about potentially making existing treatments work better—and opening new possibilities for PRP’s development. $PPCB $PPCB $RVMD $ONCY

New preclinical research from an academic–industry collaboration involving the Universities of Jaén and Granada, led by Dr. María Belén Toledo, highlights $PPCB’s PRP potential in chemotherapy-resistant pancreatic cancer. Key findings in laboratory models: • 54% reduction in resistant cancer cell proliferation. • 47% reduction in invasive capacity. • 39% reduction in long-term colony formation. Importantly, PRP pre-treatment followed by chemotherapy produced the strongest functional response observed in the study. These findings support further investigation of PRP as a potential strategy to weaken chemotherapy resistance and improve treatment sensitivity. $PPCB $BMY $MRK

$PPCB 1576 watchers all got taken to the cleaners by this stock. When is the next reverse split. Where is the stock buyback. One of these two things will happen. One won't. Which will it be? I will start. Reverse split.

$PPCB Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells

$PPCB new 52 week low on PR 😂 for such a low float stock. The people are seeing through the fraud……

$PPCB i called out this one! Unlimited reverse splits and offerings.. and finally will get thrown out to OTC! This is exactly like $TCBP

$PPCB lol. ANOTHER REVERSE SPLIT. SEC NEEDS TO HALT TRADING OF THIS STOCK. REMOVE IT FOREVER.

$PPCB notified Nasdaq of a delisting notice for failing the $1.00 bid price, with appeal planned by Oct 30.